Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
Autor: | Juan Guillermo Lopez, Arturo Galindo-Fraga, Maria de Lourdes Guerrero, Felipe Aguilar-Ituarte, Fabián P. Alvarez, Guillermo M. Ruiz-Palacios, Patricia Cervantes, Lucile Bellier, John H. Beigel, Ramiro Tamayo |
---|---|
Rok vydání: | 2019 |
Předmět: |
Quadrivalent Inactivated Influenza Vaccine
medicine.medical_specialty Cost-Benefit Analysis Immunology economic analysis Seasonal influenza vaccine cost Influenza Human public health impact medicine Humans Immunology and Allergy Economic analysis Prospective Studies Economic impact analysis Mexico Retrospective Studies Pharmacology business.industry Public health Strain (biology) virus diseases Influenza a vaccination influenza B virus Virology Vaccination Budget impact Vaccines Inactivated Influenza Vaccines seasonal influenza Public Health influenza business Research Paper |
Zdroj: | Human Vaccines & Immunotherapeutics |
ISSN: | 2164-554X 2164-5515 |
Popis: | Most influenza vaccines in Mexico are trivalent, containing two influenza A strains and a single B strain. Quadrivalent influenza vaccines (QIVs) extend protection by including an additional B strain to cover both co-circulating B lineages. Here, we retrospectively estimated how a switch to QIV in Mexico would have impacted influenza-related health outcomes over the 2010/2011 to 2015/2016 influenza seasons, and prospectively estimated the budget impact of using QIV in Mexico’s national immunization program from 2016/2017 to 2020/2021. For the retrospective estimation, we used an age-stratified static model incorporating Mexico-specific input parameters. For the prospective estimation, we used a budget impact model based on retrospective attack rates considering predicted future vaccination coverage. Between 2010/2011 and 2015/2016, a switch to QIV would have prevented 270,596 additional influenza cases, 102,000 general practitioner consultations, 140,062 days of absenteeism, 3,323 hospitalizations, and 312 deaths, saving Mex$214 million (US$10.8 million) in third-party payer costs. In the prospective analysis, a switch to QIV was estimated to prevent an additional 225,497 influenza cases, 85,000 general practitioner consultations, 116,718 days of absenteeism, 2,769 hospitalizations, and 260 deaths, saving Mex$178 million (US$9 million) in third-party payer costs over 5 years. Compared to the trivalent vaccine, the benefit and costs saved with QIV were sensitive to the distribution of influenza A vs. B cases and trivalent vaccine effectiveness against the mismatched B strain. These results suggest switching to QIV in Mexico would benefit healthcare providers and society by preventing influenza cases, morbidity, and deaths, and reducing associated use of medical resources. |
Databáze: | OpenAIRE |
Externí odkaz: |